Clinical Research Directory

Inclusion Criteria: * Singleton pregnancy between 36+0 and 41+6 weeks of gestation. * Baseline Non-Stress Test (NST) classified as non-reactive after a standard 20-minute recording (absence of ≥2 accelerations of ≥15 beats per minute lasting ≥15 seconds). * Intact amniotic membranes and not in active labor (cervical dilation \<4 cm, with absent or irregular contractions). * Ability to provide written, informed consent. * Literacy: Ability to read and write (to ensure comprehension of the consent form and study materials). * Access to a telephone or electronic device for the 24-hour safety follow-up contact. Exclusion Criteria: 1. Pregnancy-related exclusions: * Multiple gestation (twins, triplets, etc.). * Known major fetal malformation. * Diagnosis of severe fetal growth restriction with abnormal umbilical artery Doppler. * Premature rupture of membranes. * Active vaginal bleeding or placenta previa with hemorrhage. * Suspected or confirmed chorioamnionitis. 2. Maternal medical exclusions: * Severe preeclampsia, eclampsia, or HELLP syndrome. * Uncontrolled severe hypertension. * Pregestational diabetes or gestational diabetes requiring insulin or other antihyperglycemic medication. * Capillary blood glucose level \>140 mg/dL at the time of screening. * Maternal fever ≥38°C or maternal tachycardia \>120 beats per minute. 3. Interference with test interpretation: * Use of sympathomimetic drugs within 12 hours prior to the study intervention. * Maternal cardiac arrhythmias. 4. Contraindications to the intervention: * Known allergy to cocoa or chocolate. * Severe caffeine intolerance. * Phenylketonuria. * Gastrointestinal conditions that would prevent oral intake (e.g., intractable vomiting, ileus, obstruction).